Successful Use of Argatroban During the Third Trimester of Pregnancy: Case Report and Review of the Literature

Department of Pharmacy, The Milton S. Hershey Medical Center, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Pharmacotherapy (Impact Factor: 2.2). 01/2009; 28(12):1531-6. DOI: 10.1592/phco.28.12.1531
Source: PubMed

ABSTRACT Direct thrombin inhibitors are commonly used anticoagulants in patients with known or suspected heparin-induced thrombocytopenia (HIT). All three direct thrombin inhibitors available in the United States-argatroban, bivalirudin, and lepirudin-are pregnancy category B drugs based on animal studies, but little data are available on the safety of these agents during human pregnancy. Whereas several case reports support the safe use of lepirudin, only one case report has been published with argatroban and none with bivalirudin. We describe a 26-year-old pregnant woman with portal vein thrombosis and thrombocytopenia treated with argatroban for possible HIT during her last trimester. An argatroban infusion was started at 2 microg/kg/minute during her 33rd week of pregnancy, with the dosage titrated based on the activated partial thromboplastin time; infusion rates ranged from 2-8 microg/kg/minute. Treatment continued until her 39th week of pregnancy, when labor was induced. Argatroban therapy was discontinued 7 hours before epidural anesthesia. The patient successfully delivered a healthy male newborn, devoid of any known adverse effects from argatroban. The infant was found to have a small ventricular septal defect and patent foramen ovale at birth, but it is unlikely that these were caused by argatroban since organogenesis occurs in the first trimester. Even though the cause of this patient's thrombocytopenia was later determined to be idiopathic thrombocytopenic purpura, this is an important case that adds to the literature on use of argatroban during pregnancy.

  • Source
    • "There are a small number of case reports documenting the use of argatroban in pregnacy (Young et al, 2008; Ekbatani et al, 2010; Tanimura et al, 2012). In two of these cases, argatroban was used in combination with fondaparinux with successful pregnacy outcomes (Ekbatani et al, 2010; Tanimura et al, 2012), and in another, argatroban was used continuously for 6 weeks, again with a good pregnancy outcome (Young et al, 2008). The option for subcutaneous injection favours the use of danaparoid and fondaparinux, especially in situations where prolonged anticoagulation is required; there are encouraging data using the latter in pregnancy (Knol et al, 2010). "
    British Journal of Haematology 10/2012; 159(5). DOI:10.1111/bjh.12059 · 4.96 Impact Factor
  • Source
    • "This agent, however, can cross the placenta [16]. Young et al described a pregnant woman with portal vein thrombosis and thrombocytopenia treated with argatroban for suspected HIT during the third trimester, but there exists only limited human data describing use of this agent during pregnancy [17]. Fondaparinux is another potential therapeutic option for HIT. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background A serious complication of heparin treatment, heparin-induced thrombocytopenia (HIT) is rarely observed in pregnant women. Drug therapy during pregnancy should always be chosen to minimize fetal risk. The management of HIT in pregnancy represents a medical challenge. Unlike heparins, the anticoagulants used in patients with HIT do cross the placenta, with unknown fetal effects. Case Report We present a case of a 24-year-old female presenting for care at 34 weeks of gestation with acute pulmonary embolism treated initially with unfractionated heparin (UFH) and low molecular weight heparin (LMWH), who developed HIT. She was then successfully treated with fondaparinux. Conclusions To the best of our knowledge, this is one of the first case reports describing a successful use of fondaparinux in the treatment of HIT in a third-trimester pregnant woman, providing a novel approach for this subset of patients.
    Medical science monitor: international medical journal of experimental and clinical research 04/2011; 17(5). DOI:10.12659/MSM.881753 · 1.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives. State of the art of antithrombotics and their use recommendations during pregnancy. Methods. A review Results. Aspirin and heparins remain the safest molecules during pregnancy, and oral anticoagulants are still used for mechanical valves. Heparinoids are the methods of choice in case of heparin-induced thrombopenia but other molecules could find their place: fondaparinux at first and possibly the direct thrombin inhibitors. Thrombolysis may be used in case of life-threatening incident. At present, the new oral forms can not be used during pregnancy Conclusions. During pregnancy, all antithrombotics, except the oral forms, can be used, but the low molecular weight heparins replacing the unfractionated ones in the treatment and prevention of venous thromboembolism remain the treatment of choice.
    Thérapie 66(5):437-43. DOI:10.2515/therapie/2011061 · 0.40 Impact Factor
Show more